The government will continue with the policy of allowing 100 per cent foreign direct investment in existing pharmaceutical firms. In a Press Note, the Department of Industrial Policy and Promotion (DIPP), under the Ministry of Commerce and Industry, also said the Foreign Investment Promotion Board (FIPB) would decide on the contentious non-compete clause in special cases. “The government has reviewed the position in this regard and decided that the existing policy would continue with the condition that ‘non-compete’ clause would not be allowed except in special circumstances with the approval of the FIPB,” the DIPP said in the Press Note.